In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen
The head of the FDA’s oncology department, Richard Pazdur, M.D., is now the only FDA center director left from the prior administration, so the biopharma industry will be looking eagerly for signs of policy consistency from the upcoming public meeting.
The head of the FDA’s oncology department, Richard Pazdur, M.D., is now the only FDA center director left from the prior administration, so the biopharma industry will be looking eagerly for signs of policy consistency from the upcoming public meeting.
